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Donepezil, a highly selective acetylcholinesterase inhibitor (AChEI), is approved as a symptomatic treatment mild, moderate, and
severe Alzheimer’s disease (AD). Donepezil exerts its treatment eﬀect through multiple mechanisms of action including nicotinic
receptor stimulation, mitigation of excitotoxicity, and inﬂuencing APP processing. The use of donepezil at higher doses is justiﬁed
given the worsening cholinergic deﬁcit as the disease advances. Donepezil has been investigated in several clinical trials of subjects
with moderate-to-severe AD. While the side eﬀects are class speciﬁc (cholinergically driven), demonstrable beneﬁt has been shown
at the 10mg dose and the 23mg doses. Here, we review the clinical justiﬁcation, eﬃcacy, safety, and tolerability of use of donepezil
in the treatment of moderate-to-severe AD.
1.Introduction
Alzheimer’s disease is an age-related progressive neurological
disorder that ultimately results in cognitive and behavioral
dysfunction and functional loss. These later stages of disease
are impacting an increasingly large number of people each
year. At present, the treatment of Alzheimer’s disease (AD) is
limited to symptomatic therapy. As symptoms worsen and
the eﬀects of late-stage Alzheimer’s disease become more
severe, there is an urgent need for new and novel treatment
options. Of the 5.3 million people estimated to be aﬄicted
with AD in the United States, more than half are suspected to
have moderate-or-severe disease. Because these stages of AD
can last for several years, the diﬃculty presented to both pa-
tients and caregivers increases dramatically in advanced
stages [1].
Donepezil, a highly selective acetylcholinesterase inhibi-
tor (AChEI), is one of only two treatments approved in the
United States for use beyond the mild-to-moderate stage.
While it can slow progression modestly and treat symptoms,
it cannot halt progression of the actual disease or ultimately
stop the decline in cognitive and functional abilities. Agents
such as donepezil create notable symptomatic improvements
with modest but debatable impact on disease progression
frommildtomoderateisconcerned,decreasingspeedofpro-
gression from the earliest signs of cognitive impairment to
severe dementia and ﬁnally death [2, 3].
An important component of Alzheimer’s disease man-
agement is the group of caregivers who support Alzheimer’s
patients. As Alzheimer’s disease progresses, the demands on
the caregiver increase; often this takes a toll on the care pro-
vider in the form of health problems of their own, stress,
anxiety, depression, fatigue, and other physical and emotion-
alproblems[4].Donepezilisaval uabletr eatmento ptionnot
just for its capacity as a selective inhibitor of acetylcholin-
esterase for the patients but also for its capacity to ease the
burdenofthecaregiverbyprolongingtheADpatient’sability
to perform self-care tasks and delaying the progression of
symptoms that would impact a caregiver [5].
2. Overview
Donepezil has a mode of action based on inhibiting acetyl-
cholinesterase selectively. Cholinergic function is improved
when there are greater concentrations of acetylcholine in the
brain, and the depletion of acetylcholine that is common2 International Journal of Alzheimer’s Disease
with AD patients is positively aﬀected with a donepezil reg-
imen. Additionally, cholinesterase inhibitors hypothetically
could operate within the scope of the “amyloid hypothesis”
of AD pathogenesis. Donepezil in particular has been shown
to attenuate neurotoxicity of amyloid beta peptide Aβ as well
as inﬂuencing APP processing [6]. In accordance with the
cascade concept, therapies that directly target the accumu-
lation, aggregation, and deposition of amyloid beta peptide
Aβ42 and eﬀectively reduce the inciting event may be more
eﬀective than distally targeted treatments, such as those that
target neurotransmitter deﬁcits.
In addition to attenuating Aβ neurotoxicity, donepezil
also has an eﬀect on cholinergic deaﬀerentation. Cell bodies
inthenucleusbasalisinthebrainaretheoriginofcholinergic
tracts, the axons of which are proliﬁc in the cerebral cortex
and in the pedunculopontine nucleus with expansion into
the thalamus. Loss of cholinergic neurons in the nucleus bas-
alis are a hallmark of the earliest stages of AD. The functional
deaﬀerentation of the cholinergic neurons is thought to in-
duce Aβ production in the cerebral cortex, which is what be-
gins the cascade to neurodegeneration. Donepezil disrupts
the mechanism by which Aβ generation occurs following
cholinergic deaﬀerentation by interfering with the process
that leads to the exposing of the toxic N-terminal region of
APP during the preferential processing of the amyloid pre-
cursorprotein.Onewaydonepezilinteruptsthisprocessisby
cholinergic input to cortical neurons [7].
Donepezil also impacts nicotinic receptors in the cortex
through upregulation. At clinically relevant concentrations,
donepezil decreases the reduction of nicotinic acetylcholine
receptor expression in the cerebral cortex of AD patients and
prevents some of the reduction in nicotinic binding that cor-
relates to disease severity. This process reduces glutamate
neurotoxicity and also has been shown to inhibit excitotoxic
injury, which is signiﬁcant regarding AD pathogenesis and
progression [8].
Other mechanisms of action indicate donepezil could
provideatreatmentoptionforaﬀectingthecellularandmol-
ecular processes of neurodegeneration rather than sympto-
matic treatment. Donepezil has been found to inﬂuence ace-
tylcholinesterase isoform expression by inhibiting the expre-
ssion of the AChE-S form and causing an increase in the ex-
pression of the AChE-R form through reduction of cholin-
esterase, generating neuroprotective eﬀects [9]. Donepezil
has also been shown to upregulate nicotinic receptors in the
cerebral cortex, increasing nicotinic acetylcholine receptor
expression and nicotinic binding [10]. Furthermore, under
conditions of upregulations donepezil has been proven to
maintain neuroprotective actions are lower drug concentra-
tions and reduce glutamate toxicity [8]. Donepezil has been
shown to mitigate the eﬀects of oxidative stress in a strepto-
zotocin-induced model of dementia in mice, indicating use
against free radicals that may be implicated in AD [11].
Donepezil treatment has also resulted in improved cerebral
blood ﬂow in patients with mild cognitive impairment, with
no reduction after six months compared to statistically signi-
ﬁcant reduction in the placebo cohort [12, 13]. Potential
mechanisms of action also include enhancing neuroplastic
activitythroughcholinergicmodulation.Inrodentmodelsof
basocortical degeneration, donepezil induced cortical sprou-
ting, mitigating reduction in cholinergic neurotransmission
[14].
3. Efﬁcacy
Donepezil has been found to be one of the most eﬀective
symptomatic treatments for AD available on the market with
additional potential as a disease-modifying therapy. Many
but not all studies have shown that both when compared to
a placebo, donepezil has proven to have signiﬁcant eﬃcacy
in reducing the severity of neuropsychiatric symptoms in pa-
tientswithmild-to-moderateADandpatientsinmoresevere
stages of the disease [15]. Additionally, donepezil has been
foundtobeeﬀectiveinsymptomatictreatmentinavarietyof
dosing levels giving it variability as a treatment option. In an
open-label, multicenter, Phase 3 extension study of the safety
and eﬃcacy of donepezil in patients with Alzheimer’s disease
[15],theprimaryeﬃcacymeasuresweretheAlzheimer’sDis-
ease Assessment Scale-cognitive subscale (ADAS-Cog) and
the CDR-Sum of the Boxes (CDR-SB). These measures were
evaluated in a 152-week long extension study on patients
aged 50 and older that participated in at least one of the pre-
vious phases of donepezil trials, with a total patient number
(n)of763.Amongthispopulation,themostcommonreason
for study discontinuation (46% of discontinued patients)
was departure due to the commercialization of donepezil
after the successful completion of nonextension trials, allow-
ing for prescriptive use of the drug [15], but of those that
completed the study declined from baseline signiﬁcantly less
than the placebo arm in the same period with regards to
ADAS-Cog scores. After a three-week placebo washout, the
mean change for patients using CDR-SB scores actually im-
provedabovebaselinefortheexperimental armanddeclined
in the placebo arm.
In comparison studies with rivastigmine and galanta-
mine, speciﬁcally a 52-week trial [16] and a 12-week trial
[17] showed that regarding cognitive function, there is no
statistically signiﬁcant diﬀerence between patients treated
with donepezil versus those treated with galantamine, nor is
there a diﬀerence regarding behavior when comparing
10mg/day of donepezil to 24mg/day of galantamine. Sim-
ilarly, rivastigmine and donepezil have been found to have
comparable eﬀects on cognition and behavior [18, 19]a n d
similar gastrointestinal side eﬀects proﬁles [20].
4. Safety andTolerability
In patients with moderate-to-severe Alzheimer’s disease,
donepezilhasbeenfoundtobesafeandwelltoleratedatdos-
es up to 23mg, with an increase in adverse events over lower
dosages, most of which dissipate after the ﬁrst month of
treatment[1, 21]. In a randomized, double-blind study, 1371
patients (mean age: 73.8 years, 62.8% female, 73.5% white)
from 219 diﬀerent sites in Asia, Europe, Australia, North
America, South America, and South Africa were analyzed for
comparative eﬀects of 10mg/day donepezil and 23mg/day
donepezil. All patients had an MMSE of less than 20 andInternational Journal of Alzheimer’s Disease 3
assessed for changes in cognition and global functioning as
assessed using least square regressions as well as deviation
from baseline between the two cohorts. At the highest doses,
the most signiﬁcant adverse events reported in safety trials
were nausea, vomiting, and diarrhea; in the event that these
symptoms did not dissipate, dosages were reduced to im-
prove tolerability. Nevertheless, a certain percent of partic-
ipants did not tolerate donepezil even after the dose was
reduced. Donepezil has proven to be safe and well tolerated
aswellaseﬀectiveinthetreatmentofmoderate-to-severeAD
[21].
Donepezil has been found to be an eﬀective option for
maintaining a desirable quality of life and prolonging patient
performance of activities of daily living (ADL); under study
of 290 (mean age: 73.6 years, range 48–92) patients random-
ized into a 24-week, double-blind, placebo-controlled study,
donepezil demonstrated a vastly slower decline trajectory
than placebo in ADLS in patients with moderate-to-severe
AD [22]. Using the Disability Assessment for Dementia
(DAD), the Instrumental Acitvities of Daily living (IADL)
scale, and the Physical Self-Maintenance Scale (PSMS), re-
searchers have determined that moderate-to-severe AD pa-
tientstakingdonepezilwereimprovedintaskssuchastheuse
of household appliances, managing personal mail, moving
aroundinandoutsideofhomes,understandingexplanations
or new situations, and maintaining leisure activities as com-
pared to moderate-to-severe AD patients who took a placebo
[22, 23]. In a six-month study, assessing responder rates of
moderate-to-severe AD patients taking donepezil in a long-
term care facility, greater proportions of patients deﬁned as
responders to donepezil showed signiﬁcant stabilization or
improvement compared with placebo on individual eﬃcacy
measuresincludingthesevereimpairmentbattery(SIB)(≥0,
≥4o r≥7 points) and Mini-Mental State Examination (≥0
or ≥3 points), and positive trends on the ADCS-ADL-severe
(≥3points)andtheneuropsychiatricinventory(NPI)cluster
based on mood items. All 3 composite measures of eﬃcacy
showedasigniﬁcantlyhigherproportionofrespondersinthe
donepezil group. The responders had a similar distribution
between the 2 subgroups of cognitive and functional disease
severity at baseline. The donepezil-treated patients taking
psychotropic drugs showed signiﬁcantly greater improve-
ment on the SIB, less deterioration on the ADCS-ADL, and
had higher Clinical Global Impression of Improvement
scores and a trend toward lower NPI scores [23].
In addition to assessing patient conditions, caregivers
were assessed using the Caregiver Stress Scale (CSS) for the
ﬁrst time in a clinical trial to measure a caregiver’s status re-
garding cognitive status, overload, relational deprivation,
job-caregiving conﬂict, economic strains, role captivity, loss
of self, care-giving competence, personal gain, management
of distress, and expressive support. Statistical analysis of eﬃ-
cacywasbasedonchangefrombaselineofMMSEscores.Ac-
cording to the caregiver journal assessments, patients treated
with donepezil were more likely to be capable of interacting
with caregivers and others, engaging and being interested in
conversations with others, and enjoying leisurely activities.
Caregivers of donepezil-treated patients remained close to
their baseline assessments of stress levels while caregivers for
theplacebogroupreportedsigniﬁcantincreasesinstressover
the same period. Treatment of moderate-to-severe AD with
donepezilhasalsobeenassociatedwithamuchmoregradual
increase in time a caregiver spends caring for a patient with
progressing disease compared to patients who received a
placebo [24].
As indicated in the aforementioned Doody study, the
adverse events experienced when treated with donepezil are
transient and mild, often resolving themselves without the
need for dose modiﬁcation but in the rare cases resolution is
elusive, lowering the dosage is an eﬀective way to decrease
adverse events. 92% of patients in the study experienced
at least one treatment-related adverse event, with only 28%
(214) of patients experiencing a serious (grade 3 or 4) AE; in
the case of 27% (203), the serious nonfatal AEs experienced
was determined to be not related to donepezil treatment.
Treatment with donepezil also indicated no clinically signif-
icant results or changes in clinical laboratory tests, physical
examinations, or electrocardiograms. The results of this
study indicated that donepezil is a safe and eﬀective agent for
long-term treatment of moderate-to-severe disease [15].
5. Conclusions
It is broadly recognized that potent disease modifying agents
are needed to prevent the progression of Alzheimer’s disease.
While the “amyloid hypothesis” of AD pathogenesis is still
unproven, there is substantial evidence that suggests that
inhibiting Aβ plaque formation will be a valuable approach
for achieving this goal. But the foundation of AD manage-
ment will continue to include a cholinesterase inhibitor such
as donepezil. A multitude of well-controlled clinical studies
have demonstrated the cognitive beneﬁt of this agent. In
addition, by interfering with the process that leads to the
exposing of the toxic N-terminal region of APP during the
preferential processing of the amyloid precursor, donepezil
disrupts the mechanism by which Aβ generation occurs fol-
lowing cholinergic deaﬀerentation. As new therapeutics
come on line, the next advance in AD patient management
will come from understanding how they synergize with
donepezil or other cholinesterase inhibitors.
Going forward, the role donepezil plays in disease man-
agement should not be limited solely to cholinestrase inhi-
bition at the level of neurotransmitter. Rather, as preclinical
evidence amply demonstrates, the drug aﬀects on cellular
and molecular processes should be exploited for their depth
and breadth of inﬂuence at every stage of disease.
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